Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANTENGENE-B

2.570
-0.140-5.17%
Volume:2.08M
Turnover:5.38M
Market Cap:1.75B
PE:-4.72
High:2.680
Open:2.680
Low:2.480
Close:2.710
Loading ...

Antengene to Buy Back Up to HK$40 Million of Shares

MT Newswires Live
·
08 Apr

BRIEF-Antengene Announces Intention To Conduct On-Market Share Repurchase

Reuters
·
08 Apr

Antengene Corp - Intention to Conduct on-Market Share Repurchase

THOMSON REUTERS
·
08 Apr

Antengene Corp - to Repurchase Shares in Open Market From Time to Time at Maximum Aggregate Price of HK$40 Mln

THOMSON REUTERS
·
08 Apr

Antengene Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
23 Mar

Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials With Accelerating Multi-Market Revenue Ramp up

THOMSON REUTERS
·
21 Mar

Antengene Corporation FY Revenue RMB 92 Million

THOMSON REUTERS
·
21 Mar

Indonesian Regulator Approves NDA for Antengene's White Blood Cell Anti-Cancer Drug, Shares Up 11%

MT Newswires Live
·
05 Mar

BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For Xpovio

Reuters
·
05 Mar

Antengene Corp - Approval of Nda by Indonesia National Agency of Drug and Food Control for Xpovio

THOMSON REUTERS
·
05 Mar

BRIEF-Antengene Corp To Establish Dedicated Artificial Intelligence Department

Reuters
·
19 Feb

Antengene to Establish AI Department

MT Newswires Live
·
19 Feb

Antengene Corp - Plans to Establish a Dedicated Artificial Intelligence Department

THOMSON REUTERS
·
19 Feb

Antengene Corp - Initiative Includes on-Site Deployment of Deepseek

THOMSON REUTERS
·
19 Feb

Antengene Gets Reimbursement Nod for Multiple Myeloma Drug in Taiwan

MT Newswires Live
·
13 Feb

Antengene Announces Xpovio® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients With R/R Mm in the Region

THOMSON REUTERS
·
13 Feb

Antengene Corp - Approval of Xpovio for Public Health Insurance Coverage in Taiwan

THOMSON REUTERS
·
13 Feb

Antengene Presents Results From Two Late-Stage Clinical Studies of Selinexor at Ash 2024

THOMSON REUTERS
·
10 Dec 2024

Antengene Corp - Xpovio's Indication in Dlbcl Included in 2024 China National Reimbursement Drug List

THOMSON REUTERS
·
28 Nov 2024